TEAEsa | AML30+ (n = 111) | AML20–30 (n = 79) | p value | AML20–30 (n = 79) | RAEB-II (n = 96) | p value | RAEB-II (n = 96) | RAEB-I (n = 53) | p value |
 TE-thrombocytopeniab G3–4, % | 40.5 | 41.8 | 0.885 | 41.8 | 35.4 | 0.466 | 35.4 | 39.6 | 0.628 |
 TE-neutropeniab G3–4, % | 35.3 | 39.2 | 0.488 | 39.2 | 32.3 | 0.414 | 32.3 | 41.5 | 0.284 |
 TE-anaemiab G3–4, % | 47.8 | 53.2 | 0.591 | 53.2 | 54.2 | 0.924 | 54.2 | 47.2 | 0.487 |
 Febrile neutropenia, % | 23.4 | 12.7 | 0.075 | 12.7 | 8.3 | 0.337 | 8.3 | 10.3 | 0.643 |
 Infections G3–4, % | 49.5 | 31.6 | 0.047 | 31.6 | 22.9 | 0.239 | 22.9 | 20.8 | 0.751 |
Response | Â | Â | |||||||
 ORR (ITT), %   CR    CyCR   CRi   PR | 33.4 13.5 5.4 1.8 18.0 | 35.4 16.5 10.1 3.8 15.2 | 0.810 0.584 0.233 0.398 0.627 | 35.4 16.5 10.1 3.8 15.2 | 25.0 5.2 5.2 6.3 13.5 | 0.181 0.015 0.210 0.431 0.751 | 25.0 5.2 5.2 6.3 13.5 | 30.2 9.4 1.9 5.7 15.1 | 0.484 0.272 0.216 0.862 0.764 |
 HI without marrow responsec, % | 22.5 | 16.5 | 0.337 | 16.5 | 24.0 | 0.239 | 24.0 | 32.1 | 0.279 |
 RBC-TIc, % | 43.6 | 42.1 | 0.872 | 42.1 | 28.3 | 0.100 | 28.3 | 58.3 | <0.001 |
 PLT-TIc, % | 38.7 | 47.1 | 0.365 | 47.1 | 43.3 | 0.689 | 43.3 | 58.3 | 0.137 |
Outcome | Â | Â | |||||||
 30-day mortality, % | 8.1 | 6.3 | 0.635 | 6.3 | 3.1 | 0.297 | 3.1 | 0.0 | 0.078 |
 60-day mortality, % | 15.3 | 6.3 | 0.053 | 6.3 | 5.2 | 0.746 | 5.2 | 1.9 | 0.216 |
 1-year survival (total cohort), % | 49.6 | 55.7 | 0.552 | 55.7 | 70.8 | 0.179 | 70.8 | 81.1 | 0.403 |
 Median overall survival, months | 10.9 | 13.1 | 0.238 | 13.1 | 18.9 | 0.010 | 18.9 | 23.7 | 0.302 |